{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:18:28Z","timestamp":1784647108130,"version":"3.55.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines provide essential tools for the control of the COVID-19 pandemic. A number of technologies have been employed to develop SARS-CoV-2 vaccines, including the inactivated SARS-CoV-2 particles, mRNA to express viral spike protein, recombinant spike proteins, and viral vectors. Here, we report the use of the vaccinia virus Tiantan strain as a vector to express the SARS-CoV-2 spike protein. When it was used to inoculate mice, robust SARS-CoV-2 spike protein-specific antibody response and T-cell response were detected. Sera from the vaccinated mice showed strong neutralizing activity against the ancestral Wuhan SARS-CoV-2, the variants of concern (VOCs) B.1.351, B.1.617.2, and the emerging B.1.1.529 (omicron). This finding supports the possibility of developing a new type of SARS-CoV-2 vaccine using the vaccinia virus vector.<\/jats:p>","DOI":"10.3389\/fimmu.2022.911164","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T07:49:21Z","timestamp":1658476161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate"],"prefix":"10.3389","volume":"13","author":[{"given":"Shan","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangling","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"B1","volume-title":"Who coronavirus (Covid-19) dashboard","year":""},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, bbibp-corv, with potent protection against sars-Cov-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated sars-Cov-2 vaccine, bbibp-corv: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored covid-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-Human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against sars-Cov-2 on safety and immunogenicity outcomes interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA-J Am Med Assoc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against sars-Cov-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of Chadox1 ncov-19 vaccine administered in a prime-boost regimen in young and old adults (Cov002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"397","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/Nejmc2032195","article-title":"Durability of responses after sars-Cov-2 mrna-1273 vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for covid-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for covid-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03108-4","article-title":"A vaccine targeting the rbd of the s protein of sars-Cov-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284","article-title":"DNA Vaccine protection against sars-Cov-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03099-2","article-title":"Chadox1 ncov-19 vaccine prevents sars-Cov-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the Chadox1 ncov-19 vaccine against sars-Cov-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against sars-Cov-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against sars-Cov-2-Mediated pathogenesis in mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3035-9","article-title":"A single-dose live-attenuated Yf17d-vectored sars-Cov-2 vaccine candidate","volume":"590","author":"Sanchez-Felipe","year":"2021","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/J.Ebiom.2020.103132","article-title":"Newcastle Disease virus (Ndv) expressing the spike protein of sars-Cov-2 as a live virus vaccine candidate","volume":"62","author":"Sun","year":"2020","journal-title":"Ebiomedicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi5246","article-title":"Protection of K18-Hace2 mice and ferrets against sars-Cov-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based covid-19 vaccine","volume":"7","author":"An","year":"2021","journal-title":"Sci Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009383","article-title":"Inactivated rabies virus vectored sars-Cov-2 vaccine prevents disease in a Syrian hamster model","volume":"17","author":"Kurup","year":"2021","journal-title":"PLoS Pathog"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/Vaccines9080850","article-title":"A single-cycle influenza a virus-based sars-Cov-2 vaccine elicits potent immune responses in a mouse model","volume":"9","author":"Koonpaew","year":"2021","journal-title":"Vaccines-Basel"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.02.001","article-title":"A modified vaccinia Ankara vector-based vaccine protects macaques from sars-Cov-2 infection, immune pathology, and dysfunction in the lungs","volume":"54","author":"Routhu","year":"2021","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the covid-19 candidate vector vaccine mva-Sars-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"P Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic sars-Cov-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026785118","article-title":"One or two injections of mva-vectored vaccine shields Hace2 transgenic mice from sars-Cov-2 upper and lower respiratory tract infection","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","volume-title":"Vaccines\/Covid-19 vaccine eul issued","year":""},{"key":"B27","article-title":"Anterior cruciate ligament tears: Assessment, treatment","volume":"115","author":"Franco","year":"1988","journal-title":"Va Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060557","article-title":"Genomic sequence and virulence of clonal isolates of vaccinia virus tiantan, the Chinese smallpox vaccine strain","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/Cvi.00678-13","article-title":"Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein","volume":"21","author":"Remy-Ziller","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/vim.2012.0055","article-title":"Biological properties of H5 hemagglutinin expressed by vaccinia virus vector and its immunological reactivity with human sera","volume":"26","author":"Noisumdaeng","year":"2013","journal-title":"Viral Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104337","article-title":"Evaluation of a new recombinant oncolytic vaccinia virus strain glv-5b451 for feline mammary carcinoma therapy","volume":"9","author":"Adelfinger","year":"2014","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066894","article-title":"Improving adaptive and memory immune responses of an Hiv\/Aids vaccine candidate mva-b by deletion of vaccinia virus genes (C6l and K7r) blocking interferon signaling pathways","volume":"8","author":"Garcia-Arriaza","year":"2013","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/970424","article-title":"Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: Vaccinia tiantan strain","volume":"2011","author":"Lu","year":"2011","journal-title":"J BioMed Biotechnol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.antiviral.2018.03.004","article-title":"Improved immune response against hiv-1 env antigen by enhancing eev production Via a K151e mutation in the A34r gene of replication-competent vaccinia virus tiantan","volume":"153","author":"Yu","year":"2018","journal-title":"Antivir Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043730","article-title":"Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based hbv vaccine","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.075","article-title":"Broad hiv-1 neutralizing antibody response induced by heterologous Gp140\/Gp145 DNA prime-vaccinia boost immunization","volume":"30","author":"Liu","year":"2012","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.070","article-title":"Intranasal immunization with recombinant vaccinia virus tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice","volume":"37","author":"Xie","year":"2019","journal-title":"Vaccine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.04.059","article-title":"Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel hbv subunit vaccine induced more robust and lasting immunity in rhesus macaques","volume":"35","author":"Deng","year":"2017","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.122","article-title":"The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis c virus vaccine induces robust immunity in macaques","volume":"21","author":"Wen","year":"2013","journal-title":"Mol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083274","article-title":"A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5n1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice","volume":"8","author":"Xiao","year":"2013","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422x-9-322","article-title":"Influenza a virus nucleoprotein derived from escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice","volume":"9","author":"Huang","year":"2012","journal-title":"Virol J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1830715","article-title":"Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for sars-Cov-2 entry and neutralization assays","volume":"9","author":"Li","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl6184","article-title":"Rapid assessment of sars-Cov-2-Evolved variants using virus-like particles","volume":"374","author":"Syed","year":"2021","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02260-20","article-title":"Covid-19 vaccine candidates based on modified vaccinia virus Ankara expressing the sars-Cov-2 spike induce robust T- and b-cell immune responses and full efficacy in mice","volume":"95","author":"Garcia-Arriaza","year":"2021","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020132","article-title":"Localized and systemic immune responses against sars-Cov-2 following mucosal immunization","volume":"9","author":"Chandrasekar","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257191","article-title":"Vaccinia virus-based vaccines confer protective immunity against sars-Cov-2 virus in Syrian hamsters","volume":"16","author":"Kulkarni","year":"2021","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772240","article-title":"Intranasal delivery of mva vector vaccine induces effective pulmonary immunity against sars-Cov-2 in rodents","volume":"12","author":"Bosnjak","year":"2021","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41541-021-00405-5","article-title":"Mucosal vaccination induces protection against sars-Cov-2 in the absence of detectable neutralizing antibodies","volume":"6","author":"Zhong","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41541-021-00410-8","article-title":"Mva vector expression of sars-Cov-2 spike protein and protection of adult Syrian hamsters against sars-Cov-2 challenge","volume":"6","author":"Meseda","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.03.006","article-title":"Intranasal administration of a recombinant rbd vaccine induced protective immunity against sars-Cov-2 in mouse","volume":"39","author":"Du","year":"2021","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100054","article-title":"Cellular and humoral immune responses in mice immunized with vaccinia virus expressing the sars-Cov-2 spike protein","volume":"206","author":"Harbour","year":"2021","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.10.008","article-title":"Single-dose replicating poxvirus vector-based rbd vaccine drives robust humoral and T cell immune response against sars-Cov-2 infection","volume":"30","author":"Boulton","year":"2022","journal-title":"Mol Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410x(97)00039-X","article-title":"Addition of the Msa1 signal and anchor sequences to the malaria merozoite surface antigen 1 c-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus","volume":"15","author":"Yang","year":"1997","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.6.9.3191","article-title":"Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity","volume":"6","author":"Langford","year":"1986","journal-title":"Mol Cell Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.911164\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T07:49:26Z","timestamp":1658476166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.911164\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2022.911164"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.911164","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"article-number":"911164"}}